POZ - Latino Hub : News : Successful HIV Vaccine Trial Poses New Questions for Researchers

POZ Latino / Hispanic Hub
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:
 

Back to home » News & Views » News


 

February 2011
January 2011
December 2010
November 2010
October 2010
September 2010
August 2010
July 2010
June 2010
May 2010
April 2010
March 2010
February 2010
January 2010
December 2009
November 2009
October 2009
September 2009
August 2009
July 2009
June 2009
May 2009
April 2009
March 2009
February 2009
January 2009
December 2008
November 2008
October 2008
September 2008
August 2008
July 2008
June 2008
May 2008
April 2008
March 2008
February 2008
January 2008
December 2007
November 2007
October 2007
September 2007
August 2007
July 2007
June 2007
May 2007
April 2007
March 2007
February 2007


emailrssprint

September 25, 2009

Successful HIV Vaccine Trial Poses New Questions for Researchers

While a successful trial of the RV 144 HIV vaccine is a major step forward in HIV/AIDS research, experts say that the vaccine’s efficacy provides few answers but raises many questions, aidsmap.com reports. In a Thailand-based trial—the largest ever staged for an HIV vaccine—RV 144 reduced the risk of HIV infection by more than 30 percent in participants.

“This trial poses fundamental ‘black box’ questions,” said Anthony Fauci, MD, director of the National Institute of Allergy and Infectious Diseases (NIAID), which funded the trial alongside the Thai Ministry of Public Health, the United States Army and patent-holders to the two parts of the vaccine, Sanofi-Pasteur and Global Solutions for Infectious Diseases. 

He continued, “What are the correlates of HIV immunity? Has this trial overturned our understanding of what might constitute a protective response to HIV? Can we improve on this efficacy? And does this result mean we should refocus more on clinical research than basic science? Not at all. NIAID’s commitment to keeping an appropriate balance between basic science and vaccinology versus empirical clinical trials has not changed.”

According to the article, some scientists viewed the RV 144 trial as a waste of money given its $105 million price tag.

“We did hesitate to continue the trial because of the criticism from the scientific point of view,” said principal investigator Supachai Rerks-Ngarm, MD. “But in view of the need for an HIV vaccine, and in consultation with many international experts, we decided to move forward. That determination turned out to be very significant.”

NEW! Scroll down to comment on this story.

emailrssprint

 

Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

| Posting Rules

Previous Comments:

  comments 1 - 2 (of 2 total)    

Alabi JO, Warri, Nigeria, 2009-10-19 09:50:43
Since this vaccination program is just a trial, we should be ascertained that it will yield the desired result when exposed. If otherwise, the trial should be called-off.

betty boop, BROOKLYN,NY, 2009-09-28 12:22:51
my son is living with hiv. he isn't do too good. he's in and out of the hospital for an over doseing or seizers. i feel he's giving up. i'm at my witts end. i would like to join a on line group. so i can talk to someone that understands what im going through.

comments 1 - 2 (of 2 total)    


[Go to top]

Protesters hold the Hershey Company and its affiliated school accountable for condoning HIV-related discrimination. Click here to read more.
What to do if you've just been diagnosed
Qué hacer si eres recién diagnosticado

How to find a support system
Cómo encontrar un sistema de apoyo

Things you should know before starting treatment
Cosas que deberías saber antes de comenzar un tratamiento

How to handle side effects and other concerns
Cómo tratar los efectos secundarios y otros problemas de salud

How to tell someone you have HIV/AIDS
Cómo revelar tu diagnóstico de VIH/SIDA
[an error occurred while processing this directive]
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2012 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.